The Arterial Network was informed for the first time that Dinkun Technology recently announced the completion of the A-round A-share financing, which was jointly led by Huagai Capital and Morningside Capital, and the angelic investor Yuanyi Capital continued to follow suit.
After this round of financing, Diankun Technology will continue to increase scientific research, expand product lines, build a more comprehensive and better medical and enterprise cooperation mechanism, promote the construction of integrated platform for cardiovascular and cerebrovascular artificial intelligence diagnosis and treatment, and realize early warning and artificial of big data. Intelligent image screening, artificial intelligence multidisciplinary comprehensive and accurate diagnosis, personalized treatment plan planning and risk prediction, and the whole process of intelligent diagnosis and treatment integration. At present, there are more than 50 hospitals signed by Dunkun Technology, 90% of which are top three hospitals.
In response to this financing, this round of joint ventures, Huagai Capital, Morningside Capital and Angel Investor Yuanyi Capital also shared their views.
Mr. Yang’s angel investor and the current round of investment, Mr. Yang Ruirong, founding partner of Yuanyi Capital, said: “Yuanyi Capital focuses on investing in medical health and innovative finance, and is committed to finding the most innovative tomorrow in the world. Star. Yuanyi pays attention to the growth opportunities, team quality and core competitiveness of the company. The founding team of Dingkun has a very deep accumulation in artificial intelligence, big data and medical imaging, and the team's strategic ability and execution ability are outstanding. During the year, the AI ​​products of coronary heart disease were completed from research and development to the use of the top three hospitals and received praise from experts and doctors. Now many AI products only solve the fragment problem in a diagnosis scene, and the digital AI products of the number Kun are solved. It is a complete medical imaging diagnostic scenario that covers the entire process from filming to reporting. This is the future of the AI ​​application we see."
Mr. Liu Qin, the founding partner of Morning Wheel Capital, said: “Chowching Capital believes that the global medical industry will continue to have tremendous opportunities for change in the coming decades, including genetic technology and computational science. A series of technological innovations will continue to promote the global medical industry to take off. China's medical industry will also face tremendous opportunities for change in the next decade due to factors such as consumption upgrades and population aging. In this area, the drivers of technology leverage It will be one of the most important means of solving medical problems. Therefore, like Zunku Technology, it can be based on the future perspective of the medical industry, with strong technical capabilities as the core driving ability, but also rooted in existing medical care. The comprehensive team that implements the business model based on the upgrade and transformation of the system is exactly what Chenxing sought when deploying the medical industry. It is believed that Dinkun will be a vital innovation force in the future medical industry."
As the co-leader of this round, Mr. Zeng Zhiqiang, the managing partner of Huagai Capital Medical Fund, said: “Hugai Medical is an equity investment fund focusing on the medical and health industry, focusing on biomedicine, medical devices, medical services and other fields. The imaging field has already deployed most of the medical imaging product lines including CT, MRI, DSA, and color ultrasound, and is confident in the future of big data and new artificial intelligence technologies in the medical imaging industry. Our judgment on AI projects is mainly based on commercialization. Three aspects of data and algorithms. The commercialization of Diankun Technology did not cut into the red sea areas such as lung nodule detection, breast cancer screening, bone age, sugar net diagnosis, etc., but the selection gradually increased from the patient population. At the beginning of the cardiovascular and cerebrovascular diseases, the company's products have been connected to Beijing Friendship Hospital, the First Affiliated Hospital of Zhengzhou University and other super-three hospitals for operation, which has been well received by hospital experts. In terms of data, the company continues to cooperate with a large number of well-known hospitals to support the company. In the early development process, a very high quality, clinically diagnosed gold standard was obtained. Precise data for deep learning, and the company has a complete workflow and quality control mechanism in data marking; and algorithm, the main creative personnel from IBM Waston, Nobel Prize team, AI competition world champion and other biomedical and computer science fields The cross-border talents have strong strength in the original research and development of algorithms. We believe that Dunkun Technology plays an important role in the future of smart healthcare."
Cardiovascular AI products have been well received by doctors and their business covers the whole country.
As an industry-leading artificial intelligence medical technology company, Diankun Technology has not taken the usual path from the very beginning, relying on its strong scientific research strength, and has chosen deep-rooted diseases such as cardiovascular and cerebrovascular diseases. CoronaryDoc, the world's first artificial intelligence diagnostic product for cardiovascular disease, has been launched to achieve the “Polaroid†for coronary diagnostic reporting.
“With the aging of the aging, there are more and more patients with coronary heart disease, and the diagnosis of coronary imaging is very time-consuming and labor-intensive. A patient from the filming, after image processing, initial report, final review, the best situation is also It takes half an hour, usually the next day to get the report. Diankun's coronary AI products entered our hospital from the end of last year and have achieved very good clinical results so far. First, the entire diagnostic process is complete. Automation, intelligence, post-processing and initial report can basically be completed by AI. Secondly, due to the inherent quantitative analysis advantages of AI, it can meet many needs of cardiology, and it is convenient for the imaging department to provide better service clinical means. Finally, the number of Kun Guanguan The structured report of the pulse AI output in line with international standards makes our report more consistent, unified standards, and easy for reviewing doctors' review. We also look forward to working with Dunkun in other diseases to promote AI in the direction of image diagnosis. Landing." Yang Zhenghan, director of the Department of Radiology, Beijing Friendship Hospital, Capital Medical University.
“In fact, compared to other visible AI products, the threshold for cardiovascular and cerebrovascular AI is higher and the technical challenge is greater, so almost no one is doing it. We chose this kind of disease as an entry point, on the one hand because of the heart. Cerebrovascular disease is the leading cause of death, and the demand for doctors and patients is obvious. On the other hand, the diagnosis process of cardiovascular diseases is complicated, the technical threshold is high, and the development is not widespread. Many primary hospitals cannot carry out. For this reason, we provide Expert-level, comprehensive diagnostic platform covering the whole process will have great social value for improving the diagnostic efficiency of large hospitals and popularizing the prevention and treatment of cardiovascular diseases," said Ma Chunxi, CEO of Digital Technology.
Nowadays, the product has entered the clinical use of hospitals including Beijing Friendship Hospital affiliated to Capital Medical University, First Affiliated Hospital of Zhengzhou University, Wuhan Central Hospital, and Hanzhong Central Hospital, which greatly improved the doctor's work efficiency and diagnostic efficiency. And can directly improve the level of diagnosis and treatment of primary hospitals. The contracted hospitals cover leading hospitals in core cities such as Beijing, Shijiazhuang, Tianjin, Shenyang, Wuhan, Chongqing, Hangzhou, Shanghai and Guangzhou, as well as municipal hospitals in Hanzhong, Yongzhou and Aksu, achieving cross-regional and cross-level three-dimensional business layout. .
Focus on the integration of cardiovascular and cerebrovascular artificial intelligence diagnosis and treatment platform to achieve clinical assistant decision-making and smart medical layout
After the completion of the financing, Diankun Technology will continue to expand the cooperative medical institutions across the country, allowing products to be stationed in more hospitals, and effectively assisting in the clinical solution to the uneven medical resources and the diagnosis of large differences in water products. At the same time, Diankun will use cardiovascular full-cycle products to promote the construction of “medical associationsâ€, realize the interconnection of medical data, and enable high-quality medical resources in developed areas to enter the primary hospitals, so that patients can enjoy expert level in county-level hospitals. Image diagnostic service.
"In product layout, we extend from cardiovascular disease to AI diagnosis of cardiovascular and cerebrovascular diseases, including diagnosis of head and neck vascular disease, diagnosis of nervous system diseases, coronary FFRct, diagnosis of aortic disease, and diagnosis of kidney and pulmonary artery diseases. "Product development." Ma Chunxi said, "We build intelligent medical, precision medical and personalized medical health platforms through advanced artificial intelligence technology. Platforms include big data early warning, artificial intelligence image screening, artificial intelligence multidisciplinary comprehensive and accurate diagnosis, The whole process of personalized treatment plan planning and risk prediction, and the integration of intelligent diagnosis and treatment in the whole scene."
Ma Chunxi said: "Diankun Technology is a major disease as a unit to overcome, rather than a small single link in the disease, truly realize the disease brain." For example, the digital AI products of the company have been running through the coronary heart disease From early detection, diagnosis, treatment to out-of-hospital follow-up, we provide a comprehensive solution for diagnosis and treatment with patients and diseases as the center. According to her, in the second half of 2018, the products of Digital Technology will expand from heart disease to cerebrovascular diseases.
In addition, Diankun Technology will work closely with medical service companies to use artificial intelligence technology to help their products create more added value. And the products of the company can also join the multi-channels of these enterprises and enter more hospitals. Ma Chunxi said: "The cooperation between Dinkun Technology and other companies is based on the value-added service model, which enables the products of both parties to achieve the effect of 1+1>2, and the greater the magnification, the better for both partners."
In terms of the commercialization of AI, Ma Chunxi also gave his own opinion: "Why is the commercialization of artificial intelligence enterprises difficult now, because the value you create has not reached the level that customers are willing to pay, and can not make customers feel dependent. There is no business model for products."
She believes that the commercialization of any industry will go through three phases: the technology verification phase, the business model validation phase, and the new service model innovation phase. For now, medical AI is still in its first stage, and it is too early to talk about commercialization. "The medical industry is different from the rhythm of the Internet industry. There is no way to make a large-scale economy through several rounds of rapid financing like taxis and takeaways," Ma Chunxi said.
“Seeing Qiankun in the dataâ€, in the future, Diankun Technology will rely on its own powerful medical data center and artificial intelligence research platform, coordinate research institutes and medical institutions, continuously optimize and upgrade products, and realize Internet smart medical care. mode. At the same time, according to the patient's full-scale data, the patient is provided with a personalized health management program, truly intelligent integrated medical treatment, and promotes medical upgrading and national health level upgrade.
Seafood Mix,Squid And Mussel Meat Mix,Monkfish And Shrimp Mix,Frozen Seafood Mix With Octopus
Zhoushan Haiwang Seafood Co., Ltd. , https://www.haiwangseafoods.com